Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2019
Reporting Period: Event date February 11, 2019
Business Context: The Company is an emerging growth company focused on developing novel therapies. This filing discloses a specific grant award related to its clinical development program.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The only specific financial figure disclosed is a non-recurring grant award.
- Grant Award: $1,000,000 from the Alzheimer's Association.
- Payment Terms: To be paid in tranches over the course of the Phase 1 clinical trial.
Material Changes
The filing reports a material event regarding the Company's funding and clinical development pipeline:
- Grant Award: Inmune Bio was awarded a $1,000,000 grant under the "Part the Cloud to RESCUE" initiative.
- Program Focus: The funds are designated to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer's disease.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the grant to support the advancement of XPro1595 into or through its Phase 1 clinical trial.
Outlook: The award supports the progression of the Phase 1 clinical trial for XPro1595.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard implications of clinical trial execution. The receipt of funds is contingent upon the progression of the Phase 1 trial, as payments are structured in tranches.
Investor Verification Checklist
- Verify the specific milestones required to trigger each tranche of the $1,000,000 grant payment.
- Review the attached press release (Exhibit 99.1) for detailed information on the XPro1595 clinical trial design and timeline.
- Confirm the Company's current cash runway and whether this grant significantly alters its immediate liquidity position.
- Monitor future filings for updates on the Phase 1 trial status and actual receipt of grant funds.